Helix Biopharma (OTCMKTS:HBPCF) Posts Earnings Results

Helix Biopharma (OTCMKTS:HBPCF) released its quarterly earnings results on Monday. The company reported ($0.01) earnings per share (EPS) for the quarter, Zacks reports.

Helix Biopharma Stock Performance

HBPCF remained flat at $1.73 during midday trading on Wednesday. Helix Biopharma has a 52-week low of $0.59 and a 52-week high of $1.73. The stock has a market cap of $132.42 million, a PE ratio of -28.90 and a beta of -0.17. The business’s fifty day simple moving average is $1.73 and its 200 day simple moving average is $1.44.

About Helix Biopharma

Helix BioPharma Corp is a clinical‐stage biotechnology company focused on the research, development and commercialization of immunotherapeutic drug candidates for oncology and rare disease indications. Headquartered in Laval, Quebec, the company leverages proprietary platforms designed to activate or modulate the immune system, with programs spanning small‐molecule immunoconjugates and biologic modalities. Its lead candidate, L-DOS47, is an antibody‐based immunoconjugate in clinical evaluation for non–small cell lung cancer, and Helix maintains additional discovery‐stage assets targeting solid tumors and hematological malignancies.

Founded in 1983, Helix BioPharma has built a global network of collaborations with academic research centers and contract research organizations across North America and Europe.